Week in Review: WuXi NextCode Leads $15 Million Financing in Claritas Genomics

WuXi PharmaTech, through its WuXi NextCODE Genomics subsidiary, led a $15 million Series B financing in Boston's Claritas Genomics; Armetheon of San Francisco raised $24.3 million from Taiwan/China sources in a Series B to advance its oral anticoagulant; Merck is pulling out of its high profile China branded generic drug JV with Simcere Pharma; Harbin Gloria Pharma will pay $380 million to acquire an 85% stake in Shanxi Powerdone; Hainan Shuangcheng Pharma purchased a 56% stake in Hangzhou Ausia BioTech for $154 million; BBI Life Sciences, a Shanghai-based lab services company, completed a $37.4 million IPO in Hong Kong; UCB of Belgium reported positive results from two China Phase III trials of Neupro, a patch product for Parkinson's disease; and ChemPartner, the preclinical CRO/CMO division of China's ShangPharma, opened a 24,000 square foot lab in South San Francisco, its first facility outside of China. More details.... Stock Symbols: (NYSE: WX) (NYSE: MRK) (SHE: 002437) (SHE: 002693) (HK: 1035) (Euronext: UCB) Share this with colleagues: // //